FDA Approves the Next Best thing for Opioid Addiction - Miracle Recovery Center
16156
post-template-default,single,single-post,postid-16156,single-format-standard,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode-theme-ver-11.2,qode-theme-bridge | shared by vestathemes.com,wpb-js-composer js-comp-ver-5.2.1,vc_responsive

FDA Approves the Next Best thing for Opioid Addiction

FDA Approves the Next Best thing for Opioid Addiction

 

‘Lucemyra’ could be the next best thing in addiction treatment

By, Ivy Chase.

Opioid Addiction is at an all time high in America, it’s been claimed  a complete state of crisis for the nation.  A non opioid drug called Lucemra has been approved by the FDA to mitigate withdrawal symptoms after abrupt discontinued use of opioids.

Part of the turn off for individuals who go off opioid painkillers and even harsher opiates is the idea of facing the excruciating withdrawal symptoms such as nausea, anxiety, vomiting, muscle aches and more, most resembling a terrible flu bug.  Currently, the FDA has given it’s approval for US World Meds new medication called Lucemyra, the first drug designed to fight the opioid withdrawal symptoms.

The drug was approved after showing that it reduced severe withdrawal symptoms better than the placebo did.  Individuals who participated in the drug trial, consuming the drug completed a seven day opioid discontinuation treatment.  These symptoms were a vast improvement from the group of participants who took the placebo.

The New Concept of the lack of suffering

The UK has been using Lucemyra for more than two decades.  They have said that the drug (which is administered orally), isn’t meant to treat opioid addiction or curb drug cravings, however it is most effectively used as part of a long term plan or treatment for quitting powerful painkillers and staying opioid-free long term, commented the FDA on it’s benefits.

Long term medication assisted addiction therapy such as the Vivitrol shot or Naltrrexone blocks the effects of opioids on the brain, thus one cannot feel the effects or euphoria of the drugs.  Lucemyra works by reducing and releasing norepinephrine, the very chemical believed to play such a large role in causing the body withdrawal symptoms.

The withdrawal effects from opioids is usually the main or most terrifying barrier which individuals who are physically addicted face when trying to become clean and sober, ultimately overcoming addiction.  One addicted, they become filled with mainly the overwhelming fear of going through the withdrawal symptoms, which is often the reason that prevents them from recovering and ending the pain and suffering of addiction in the first place.

Because this new drug will make the withdrawal process easier for addicts trying to recover, National Institute on Drug Abuse Director Nora Valkow, MD, argues that the drug may promote an increase and a wider use of Vivitrol, a drug that differentiates itself from methadone and buprenorphine- a couple other addiction treatments that belong to the opioid family.

America’s Solution to the Opioid Crises?

The FDA has approved Lucemyra the go ahead towards the treatment of withdrawal from Opioid addiction, claiming thousands of individuals struggling will be able to finally overcome their fear of withdrawal.  Currently the medication is only approved for up to 14 days of use.  The agency will continue to examine the drug’s long term effects and effectiveness. 

The launch of Lucemyra is projected in the U.S. in August 2018.

___________________________________________________________________________________

References:  fierce-pharms.com



000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550